EP4527378A1 — A film coated tablet of brivaracetam
Assigned to Sanovel Ilac Sanayi ve Ticaret AS · Expires 2025-03-26 · 1y expired
What this patent protects
The present invention relates to a film coated tablet comprising brivaracetam and at least one pharmaceutically acceptable excipient wherein brivaracetam has a d (0.9) particle size between 40 µm to 450 µm and lactose monohydrate and lactose anhydrous is present as diluent. Furth…
USPTO Abstract
The present invention relates to a film coated tablet comprising brivaracetam and at least one pharmaceutically acceptable excipient wherein brivaracetam has a d (0.9) particle size between 40 µm to 450 µm and lactose monohydrate and lactose anhydrous is present as diluent. Furthermore, the tablet is also obtained by using an effective process which is simple, rapid, cost effective, time-saving and industrially convenient process.
Drugs covered by this patent
- Briviact (BRIVARACETAM) · UCB
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.